Weekly Twitter Roundup

Posted by Dan Vorhaus on February 12, 2010

Each week there are a number of stories and developments that, for one reason or another, don’t find their way into a full-length posting on the Genomics Law Report. Here’s a recap of what I was Tweeting this week @genomicslawyer:

RT @jensmccabe: pharma + academia: cross-pollination between Lilly and Harvard? Interesting – http://tinyurl.com/yaecory
RT @crossborderbio: @matthewherper ‘s call for SPA transparency: http://bit.ly/as7O7K My take: http://bit.ly/aCqJ0T
Improving complex disease risk production w/ phenotypic & genotypic info from close relatives: http://bit.ly/dvb0Od (Genome Medicine)
Last tweet: “I want to build a $10 sequencer that can sequence the genome, and do it for maybe $10. That’s what we need. That’s biology.”
RT @bioitworld: Exclusive: Kevin speaks with Ron Davis about a 3rd gen sequencing platform from Ion Torrent: http://bit.ly/dnO8sn
“Personal Genomics: What Consumers and Investors Want to Know” panel last night http://bit.ly/chnLvh Great coverage from @chiah #genome
RT @Ryan_McBride: Guess who’s at Third Rock Ventures, launching a new biotech? Hint: He used to work at CombinatoRx http://bit.ly/acncMV
Personal Genomic Company Testing Comparisons from @AccessDNA http://bit.ly/aSubjP Good side-by-side comparisons of DTC providers
RT @blaine_5, @megansmolenyak: 3 mos of prime time genealogy starting tonight! Check out Faces of America http://bit.ly/5darCx
Feel guilty sitting @ desk & watching RT @tgoetz: The argument for better health in 3:53 (#thedecisiontree video) http://bit.ly/cW0hHi
Does anybody care about HIPAA anymore? http://bit.ly/bPeN5V Lax enforcement, delays reducing concerns?
A look at the business model behind @patientslikeme from @Ryan_McBride of Xconomy: http://bit.ly/aLfwwL
RT @techreview: Genetic Testing Heads to the Pharmacy: Several recent deals could make tests more common. http://bit.ly/cFAKgV
The HER2 Testing Conundrum: http://bit.ly/artmYr (via @NatureNews)
Phone-based genetic counseling vs standard counseling in women at risk of BRCA1/2 mutation http://bit.ly/7R2ixE (RT @AccessDNA, @dctrials)
Agendia receives clinical laboratory permit from NY; can now offer MammaPrint in New York: http://bit.ly/aD0MDE (via @GenomeWeb_News)
RT @DukeIGSP: DNA sequencing to be outsourced to China? @scienceprogress says yes. http://bit.ly/djmnrU
RT @DNAnetwork: RT @PHGFoundation: Pre-conceptual genetic testing for multiple conditions http://bit.ly/bTm2vO
RT @tgoetz wowzers! very cool combo of words & graphix RT @pioneerrwjf: The Coming Revolution in Health Care http://bit.ly/cTlo7V
Is a follow-on biologics pathway dead? BIO chief shows @FierceBiotech a (small) window of opportunity http://bit.ly/dyuO8t (@crossborderbio)
RT @phylogenomics: When will scientists learn? Informed consent is key to trust: Debate Over Blood From Newborn Tests http://nyti.ms/bEBHRg
SACGHS Gene Patent Recommendations Still Controversial: http://bit.ly/bC1Z8s (feat. bonus Schoolhouse Rock! Youtube clip)
NH considering (again) patient privacy bill that would expand patient notification/consent requirements under HIPAA: http://bit.ly/caRkpM
RT @mobilehealth: 1/5 Epocrates users want an iPad-not 20% of all MDs, but those already using Epocrates http://tinyurl.com/yjhq7fk
Recap – and criticism – of the snow-shortened SACGHS approval of gene patent recommendations on Fri: http://bit.ly/bfqYF8
FDA Updates Label for Warfarin to Include genetic variants as one factor (among several) for dosing recommendations: http://bit.ly/dvnPPf
RT @HFDigest: RT: @ADAM_Health FCC’s Broadband Plan Looks to Mobile Phones for Health Care – http://ow.ly/14lPS
RT @ScienceInsider: Landmark Pluripotent Patent Has Stem Cell Researchers Nervous http://bit.ly/aGY36G
RT @DukeIGSP: RT @ahier: Research on the Mexican genome could broaden scope of personalized medicine http://bit.ly/bZKU8h
RT @matthewherper: Medicine is a fight with broken biology, and biology usually wins.